IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Journal article : Review

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti–IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23–driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.

Authors: Krueger, JG; Eyerich, K; Kuchroo, VK; Ritchlin, CT; Abreu, MT

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Frontiers Media
• Journal: Frontiers in Immunology
• Volume: 15
• Article number: 1331217
• Publication date: 2024-04-15
• Acceptance date: 2024-03-21
• DOI: 10.3389/fimmu.2024.1331217
• EISSN: 1664-3224
• Language: English
• Keywords: inflammatory bowel disease; cytokine; IL-23; psoriasis; psoriatic arthritis; immune-mediated inflammatory diseases
• Subtype: Review